Related Experiment Video

Updated: Aug 30, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Opportunities for newer agents in combination with oxaliplatin

Howard S Hochster1

  • 1Department of Medicine, NYU School of Medicine, New York, NY 10016, USA.

Seminars in Oncology
|October 3, 2003
PubMed

Insights

Oxaliplatin, a platinum-based chemotherapy, is revolutionizing colorectal cancer treatment. New targeted therapies, including anti-angiogenesis and anti-HER1 agents, show promise in combination with oxaliplatin.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Oxaliplatin represents a significant advancement in third-generation platinum analogues for colorectal cancer (CRC) treatment.
  • The advent of oxaliplatin has reshaped the landscape of CRC chemotherapy strategies.

Purpose of the Study:

  • To review the role of oxaliplatin in colorectal cancer therapy.
  • To discuss novel biologic and molecular targeting agents in CRC.
  • To explore the rationale and early clinical trial results for combining oxaliplatin with emerging targeted therapies.

Main Methods:

  • Review of current literature on oxaliplatin and targeted therapies in colorectal cancer.
  • Analysis of clinical trial data for novel agents in combination with oxaliplatin.

Main Results:

  • Oxaliplatin demonstrates unique efficacy in colorectal cancer.
  • Several novel agents, including anti-VEGF antibodies, anti-EGFR antibodies (HER-1), EGFR tyrosine kinase inhibitors, and the proteasome inhibitor PS-341 (bortezomib), are in advanced clinical trials for CRC.
  • Early clinical trials suggest potential benefits from combining oxaliplatin with these targeted agents.

Conclusions:

  • Oxaliplatin has become a cornerstone in colorectal cancer chemotherapy.
  • Combination strategies involving oxaliplatin and novel molecularly targeted agents hold significant promise for improving CRC treatment outcomes.

More Related Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...